Randomized trial · people

Efinopegdutide: 72.7% liver fat drop vs 42.3% on semaglutide

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In a head-to-head trial, efinopegdutide cut liver fat more than semaglutide at these doses, with similar weight loss and somewhat more gut side effects.

Kind
Randomized trial
Studied in
People
Number studied
145
Published
2023
Journal
J Hepatol

What they tested

The team tested whether efinopegdutide, which acts on both GLP-1 and glucagon receptors, lowers liver fat more than semaglutide in people with non-alcoholic fatty liver disease (NAFLD).

How the study was done

A phase IIa randomized, open-label trial (everyone knew which drug they got) in 145 people with NAFLD and at least 10% liver fat, 33.1% of whom had type 2 diabetes. They were assigned to efinopegdutide 10 mg or semaglutide 1 mg, each given under the skin once a week for 24 weeks, with liver fat measured by MRI.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At week 24, liver fat fell by an average of 72.7% from its starting level in the efinopegdutide arm (90% CI 66.8-78.7) and by 42.3% in the semaglutide arm (90% CI 36.5-48.1), a significant gap (p <0.001). Body weight dropped 8.5% with efinopegdutide and 7.1% with semaglutide, a gap that was not statistically significant (p = 0.085). Side effects were slightly more common with efinopegdutide, mostly stomach and gut problems.

What it doesn’t show

The trial was open-label, ran only 24 weeks and compared one dose of each drug. It measured liver fat on MRI, not liver inflammation or scarring, so it does not show an effect on NASH itself.

The paper

Romero-Gómez et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. J Hepatol. 2023.

The compound

More studies on Efinopegdutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking efinopegdutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo